反応式
[F:1][C:2]([F:11])([F:10])[C:3]1[CH:4]=[C:5]([CH:7]=[CH:8][CH:9]=1)N.[CH3:12][C:13]([CH:15]=[CH2:16])=O.ClC(Cl)=O.[CH3:21][O:22][C:23]1[CH:24]=[C:25]([NH:35][C:36]([NH2:38])=[S:37])[CH:26]=[CH:27][C:28]=1[N:29]1[CH:33]=[C:32]([CH3:34])[N:31]=[CH:30]1>>[CH3:21][O:22][C:23]1[CH:24]=[C:25]([NH:35][C:36]2[S:37][C:13]([CH2:12][C:5]3[CH:7]=[CH:8][CH:9]=[C:3]([C:2]([F:11])([F:10])[F:1])[CH:4]=3)=[C:15]([CH3:16])[N:38]=2)[CH:26]=[CH:27][C:28]=1[N:29]1[CH:33]=[C:32]([CH3:34])[N:31]=[CH:30]1参加物
実験手順
The title compound was prepared in analogy to example 7 without purification of the intermediate from 161 mg (1 mmol) 3-trifluoromethylaniline and 421 mg (6 mmol) methyl vinylketone. The crude chloroketone was used without further purification in the next step with 53 mg (0.2 mmol) [3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-thiourea. The crude product was purified on silica gel with methylene chloride/methanol 19/1 yielding 50 mg (55%) [3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-methyl-5-(3-trifluoromethyl-benzyl)-thiazol-2-yl]-amine as a brown solid. MS ISP (m/e): 459.1 (100) (M+H)+. 1H NMR (DMSO-D6, 250 MHz): δ (ppm)=10.18 (s, 1H), 7.66-7.53 (m, 7H), 7.23 (s, 1H), 7.01 (s, 1H), 4.11 (s, 2H), 3.77 (s, 3H), 2.25 (s, 3H), 2.14 (s, 3H).
後処理
- customThe crude product was purified on silica gel with methylene chloride/methanol 19/1 yielding 50 mg (55%) [3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-[4-methyl-5-(3-trifluoromethyl-benzyl)-thiazol-2-yl]-amine as a brown solid
出典と根拠
- ORDレコード
- ord-832dea0fe5284aea96c203ebf2b47e5d
- 出典データセット
- uspto-grants-2011_03
- 特許番号
- US07910740B2
関連ノート
読み込み中…